Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
IPO Year: 2020
Exchange: NASDAQ
Website: legendbiotech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2026 | $24.00 | Buy → Neutral | Rothschild & Co Redburn |
| 1/22/2026 | $21.00 | Buy → Hold | TD Cowen |
| 1/7/2026 | $75.00 | Outperform | Oppenheimer |
| 10/7/2025 | $40.00 | Overweight | Cantor Fitzgerald |
| 10/8/2024 | $86.00 | Buy | Redburn Atlantic |
| 6/17/2024 | $88.00 | Buy | Truist |
| 5/24/2024 | $86.00 → $73.00 | Buy | H.C. Wainwright |
| 5/23/2024 | $60.00 | Buy | Deutsche Bank |
| 4/17/2024 | $65.00 | Sector Perform → Sector Outperform | Scotiabank |
| 4/3/2024 | $82.00 | Overweight | Cantor Fitzgerald |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Rothschild & Co Redburn downgraded Legend Biotech from Buy to Neutral and set a new price target of $24.00
TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00
Oppenheimer initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $75.00
Cantor Fitzgerald initiated coverage of Legend Biotech with a rating of Overweight and set a new price target of $40.00
Redburn Atlantic initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $86.00
Truist initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $88.00
H.C. Wainwright reiterated coverage of Legend Biotech with a rating of Buy and set a new price target of $73.00 from $86.00 previously
Deutsche Bank initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $60.00
Scotiabank upgraded Legend Biotech from Sector Perform to Sector Outperform and set a new price target of $65.00
Cantor Fitzgerald initiated coverage of Legend Biotech with a rating of Overweight and set a new price target of $82.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
144 - Legend Biotech Corp (0001801198) (Subject)
20-F - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
SCHEDULE 13G/A - Legend Biotech Corp (0001801198) (Subject)
Fastest customizable press release news feed in the world
Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignanciesAn ORR of 100% (6/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5/6) in patients with relapsed/ refractory NHLData demonstrate robust in vivo CAR-T expansion without lymphodepleting chemotherapy Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS <Grade 2 BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501,
LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78.6%, with durable responses seen in some patients New CARVYKTI® data continue to support durable efficacy and a consistent safety profile in multiple myeloma BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and AustraliaAdvanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026Cash and cash equivalents, and time deposits of $834.6 million, as of March 31, 2026. SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highl
SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguished scientific advisors who will provide strategic input as Legend advances its pipeline and future research priorities. The advisors, who include Renier Brentjens, M.D., Ph.D., Spencer Fisk, Carl June, M.D., Maximilian F. Konig, M.D., Anthony Polverino, Ph.D., and Georg Schett, M.D., bring deep expertise spanning oncology, immunology, development, and manufacturing of cell-based therapies. "These advisors bring an exceptional breadth of experience that will help guide our scientific prioritie
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients treated with CARVYKTI®CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settingsAdvanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN)
SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presen
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will present six poster presentations featuring data on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) at the Tandem Meetings of ASTCT® and CIBMTR®, taking place February 4-7, 2026, in Salt Lake City, UT. With more than 10,000 patients treated worldwide, CARVYKTI® continues to generate a growing body of clinical and real-world evidence, informing how the therapy can be op
Exceeded 10,000 patients treated to date with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy manufacturing facility in the U.S.Profitability expected in 2026, driven by continued CARVYKTI® revenue growth and operating margin expansion Treated first patient with in vivo pipeline candidate in investigator-initiated trial Preclinical data from primates provided early validation for CD20/CD19 dual-targeting in vivo CAR-T cell therapy for non-Hodgkin lymphoma SOMERSET, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a g
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14th, 2026, at 9:00 a.m. PT. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend's website. The webcast replay will be available approximately 48 hours after the webcast. ABOUT LEGEND BIOTECH With over 2,900 employees, Legend Biotech is the largest standalo
This live feed shows all institutional transactions in real time.
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
Live finance-specific insights
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and AustraliaAdvanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026Cash and cash equivalents, and time deposits of $834.6 million, as of March 31, 2026. SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highl
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients treated with CARVYKTI®CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settingsAdvanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN)
SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presen
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 millionEC and U.S. FDA label updates for CARVYKTI® to include overall survival benefit versus standard of care Over 9,000 patients treated to dateInitiated CARVYKTI® commercial production at Tech Lane facility in BelgiumCash and cash equivalents, and time deposits of approximately $1.0 billion, as of September 30, 2025 SOMERSET, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2025 unaudited financial results and key corporate highlights. "CARVYKTI continues to deliver strong sequential r
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 yearsPresented other important CARVYKTI® and new solid tumor data at ASCOOver 7,500 patients treated to dateCash and cash equivalents, and time deposits of $1.0 billion, as of June 30, 2025 SOMERSET, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2025 unaudited financial results and key corporate highlights. "The groundbreaking five-yea
SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August 11, 2025, to review second-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hour
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia's TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31, 2025, which Legend Biotech believes will provide financial runway into the second quarter of 2026 SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend
SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentations section approximately two hours
Live Leadership Updates
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025. Mr. Santos is a seasoned finance executive who has led financial operations in the pharmaceutical and technology sectors across the United States, Latin America, Europe, the Middle East, and Africa. At Legend, he will oversee financial operations to work to ensure a robust balance sheet and achieve and maintain profitability. "On behalf
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg
SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn
SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9. "We are pleased to welcome Dr. Salovey to the Legend Board," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Dr. Salovey's deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic dec
Legend Biotech Corporation ("Legend Biotech" or the "Company") (NASDAQ:LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Mythili Koneru, M.D., Ph.D. as the Company's Chief Medical Officer. In this role, Dr. Koneru will be responsible for overseeing the Company's clinical development and medical affairs programs. Dr. Koneru joins Legend Biotech from Marker Therapeutics, where she served as Chief Medical Officer, leading the development of the company's cell therapies and peptide vaccines in its immuno-oncology portfolio. Prior to her time at Marker Therapeutics, Dr. Kone
Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO and Chief Executive Officer (CEO) since September 2020. Dr. Huang will continue to serve as CEO of Legend Biotech. "Lori is a highly valued leader and strategic thought partner that has been instrumental in building the company's finance organization," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Lori p
Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development. Dr. Guowei Fang is an accomplished scientist and pharmaceutical research and development leader who brings a wealth of experience in oncology and immunology to the role. Dr. Fang comes to Legend Biotech from Zymeworks Inc, where he served as senior vice president of Research and oversaw the development of novel platforms and a portfolio of multi-functional biologics and antibody
Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech"), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotech's Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotech's Board of Directors. Dr. Huang will serve as a Class I director. "We are delighted to have Dr. Huang join our Board of Directors," said Sally Wang, Chairwoman of Legend Biotech. "As Legend Biotech's Chief Executive Officer and Chief Financial Officer, Dr. Huang has been instrumental to Legend Biotech's progress to date, and his extensive knowledge of Legend Biotech will surely enhan
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeut